Kemp Dolliver
Stock Analyst
(n/a)
# 2,858
Out of 4,648 analysts
19
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Kemp Dolliver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRCA Verrica Pharmaceuticals | Downgrades: Hold | n/a | $1.43 | - | 2 | Oct 2, 2024 | |
| ONCT Oncternal Therapeutics | Downgrades: Hold | n/a | $1.48 | - | 3 | Sep 12, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $3.6 | $2.66 | +35.34% | 1 | Jul 22, 2024 | |
| DARE Daré Bioscience | Upgrades: Buy | $36 | $3.89 | +825.45% | 2 | May 15, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $31 | $6.06 | +418.15% | 1 | Jan 25, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Downgrades: Hold | n/a | $0.51 | - | 1 | Dec 19, 2023 | |
| LNTH Lantheus Holdings | Initiates: Buy | $100 | $115.45 | -13.38% | 1 | Nov 30, 2023 | |
| EYEN Eyenovia | Initiates: Buy | $8 | $0.52 | +1,444.10% | 1 | Oct 17, 2023 | |
| EDSA Edesa Biotech | Maintains: Buy | $57 | $2.57 | +2,117.90% | 2 | Oct 12, 2023 | |
| PROC Procaps Group | Downgrades: Hold | $4.5 | $1.78 | +152.81% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $25 | $3.07 | +714.33% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $12.32 | +52.19% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $1.32 | +506.06% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5.65 | $0.85 | +564.71% | 1 | Feb 2, 2022 |
Verrica Pharmaceuticals
Oct 2, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.43
Upside: -
Oncternal Therapeutics
Sep 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.48
Upside: -
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $2.66
Upside: +35.34%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $3.89
Upside: +825.45%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $6.06
Upside: +418.15%
Cyclacel Pharmaceuticals
Dec 19, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.51
Upside: -
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $115.45
Upside: -13.38%
Eyenovia
Oct 17, 2023
Initiates: Buy
Price Target: $8
Current: $0.52
Upside: +1,444.10%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $2.57
Upside: +2,117.90%
Procaps Group
Sep 6, 2023
Downgrades: Hold
Price Target: $4.5
Current: $1.78
Upside: +152.81%
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $3.07
Upside: +714.33%
Jan 13, 2023
Initiates: Buy
Price Target: $19
Current: $12.32
Upside: +52.19%
Oct 21, 2022
Assumes: Buy
Price Target: $8
Current: $1.32
Upside: +506.06%
Feb 2, 2022
Initiates: Buy
Price Target: $5.65
Current: $0.85
Upside: +564.71%